SAVA

Cassava Sciences Inc

SAVA, USA

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

https://www.cassavasciences.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SAVA
stock
SAVA

The Truth About Cassava Sciences: Wall Street’s Wildcard Stock Everyone Keeps Arguing About AD HOC NEWS

Read more →
SAVA
stock
SAVA

Alzheimer’s drug trial data reveal blood test limits and safety clues Stock Titan

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.26

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-13.25 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-8.33 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-750.12 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Medium

0.59

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 29.00% of the total shares of Cassava Sciences Inc

1.

Vanguard Group Inc

(4.4922%)

since

2025/06/30

2.

BlackRock Inc

(3.2001%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(2.5996%)

since

2025/07/31

4.

Two Sigma Advisers, LLC

(2.0361%)

since

2025/06/30

5.

JPMorgan Chase & Co

(1.5672%)

since

2025/06/30

6.

Goldman Sachs Group Inc

(1.2692%)

since

2025/06/30

7.

Two Sigma Investments LLC

(1.0899%)

since

2025/06/30

8.

Geode Capital Management, LLC

(1.0824%)

since

2025/06/30

9.

Millennium Management LLC

(0.9787%)

since

2025/06/30

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9669%)

since

2025/07/31

11.

Morgan Stanley - Brokerage Accounts

(0.9327%)

since

2025/06/30

12.

GMT Capital Corp

(0.9317%)

since

2025/06/30

13.

Susquehanna International Group, LLP

(0.9241%)

since

2025/06/30

14.

Jane Street Group LLC

(0.7009%)

since

2025/06/30

15.

Cubist Systematic Strategies, LLC

(0.6411%)

since

2025/06/30

16.

Charles Schwab Investment Management Inc

(0.5492%)

since

2025/06/30

17.

Fidelity Extended Market Index

(0.5091%)

since

2025/07/31

18.

TANG CAPITAL MANAGEMENT LLC

(0.4964%)

since

2025/06/30

19.

State Street Corp

(0.4499%)

since

2025/06/30

20.

Group One Trading, LP

(0.4479%)

since

2025/06/30

21.

Schwab US Small-Cap ETF™

(0.4422%)

since

2025/08/30

22.

UBS Group AG

(0.3935%)

since

2025/06/30

23.

Vanguard Health Care ETF

(0.2926%)

since

2025/07/31

24.

Susquehanna Portfolio Strategies LLC

(0.2762%)

since

2025/06/30

25.

Squarepoint Ops LLC

(0.2204%)

since

2025/06/30

26.

iShares Micro-Cap ETF

(0.2025%)

since

2025/08/31

27.

Extended Equity Market Fund K

(0.1853%)

since

2025/06/30

28.

Fidelity Total Market Index

(0.1671%)

since

2025/07/31

29.

Fidelity Series Total Market Index

(0.1331%)

since

2025/07/31

30.

Spartan Extended Market Index Pool F

(0.1112%)

since

2025/07/31

31.

NT Ext Equity Mkt Idx Fd - L

(0.1059%)

since

2025/06/30

32.

Northern Trust Extended Eq Market Idx

(0.1059%)

since

2025/06/30

33.

Fidelity Nasdaq Composite Index

(0.0989%)

since

2025/07/31

34.

Avantis US Small Cap Equity ETF

(0.0763%)

since

2025/08/30

35.

Spartan Total Market Index Pool G

(0.0618%)

since

2025/07/31

36.

Vanguard Balanced Index Inv

(0.0562%)

since

2025/07/31

37.

T. Rowe Price Extended Equity Market Idx

(0.0551%)

since

2025/07/31

38.

Schwab US Broad Market ETF™

(0.0538%)

since

2025/08/30

39.

Schwab Total Stock Market Index

(0.0518%)

since

2025/07/31

40.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0429%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.27

Latest Release

Date

2025-09-30

EPS Actual

-0.22

EPS Estimate

-0.27

EPS Difference

0.05

Surprise Percent

18.5185%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.